LYTIR

Insider · SEC Form 4 · Director

MONTANOVA CAPITAL, LLC

In the 12 months to Nov 19, 2026, on the open market: sold $80.4M of MANE. Filed 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

  1. MANESold: Veradermics, Inc Aug 19, 2026 750,000 shares filed Aug 21, 2026 2 transactions filing $80.4M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. FTHMontanova Capital, LLC filed Nov 13, 2026 Schedule 13G/A passive issuer: Faeth Therapeutics, Inc. filing 8.9%
  2. IMTXMontanova Capital, LLC filed Nov 13, 2026 Schedule 13G/A passive issuer: Immatics N.V. filing 5.8%
  3. AURAMontanova Capital, LLC filed Nov 13, 2026 Schedule 13G/A passive issuer: Aura Biosciences, Inc. filing 2.9%
  4. CAPRMontanova Capital, LLC filed Nov 13, 2026 Schedule 13G/A passive issuer: Capricor Therapeutics, Inc. filing 0%
  5. FULCMontanova Capital, LLC filed Nov 13, 2026 Schedule 13G/A passive issuer: Fulcrum Therapeutics, Inc. filing 0%
  6. MANEMONTANOVA CAPITAL, LLC filed Aug 21, 2026 Schedule 13D/A may seek influence 3,718,970 shares issuer: Veradermics, Inc filing 8.8%
  7. IFRXMontanova Capital, LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: InflaRx N.V. filing 15.6%
  8. KURAMontanova Capital, LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: Kura Oncology, Inc. filing 9.7%
  9. FULCMontanova Capital, LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: Fulcrum Therapeutics, Inc. filing 5.5%
  10. GLUEMontanova Capital, LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: Monte Rosa Therapeutics, Inc. filing 4.2%
  11. ABEOMontanova Capital, LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: Abeona Therapeutics Inc. filing 0.9%
  12. REPLMontanova Capital, LLC filed Aug 6, 2026 Schedule 13G/A passive issuer: Replimune Group, Inc. filing 7.9%
  13. SNSESUVRETTA CAPITAL MANAGEMENT, LLC filed Jun 23, 2026 Schedule 13G passive issuer: Faeth Therapeutics, Inc. filing 7.8%

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • MANE: in-the-money exercise (code X), 2 entries, Aug 20, 2026
Code X
An exercise of an in-the-money or at-the-money derivative security.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.